Indeed, many HER2-targeting drugs, such as the humanized monoclonal antibody (trastuzumab and pertuzumab) [12, 13], dual inhibitor of EGFR/HER-2 (lapatinib) [14], and pan-inhibitor of EGFR/HER2/HER4 (afatinib) [15], are already undergoing clinical trials in NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.